| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 1/200 - 1/1000 | Human,Mouse,Rat |
| FCM | 1/200 - 1/400 | Human,Mouse,Rat |
| Elisa | 1/10000 | Human,Mouse,Rat |
| Aliases | ET1; QME; PPET1; ARCND3; HDLCQ7 |
| Entrez GeneID | 1906 |
| clone | 4E6E5 |
| WB Predicted band size | 24.4KDa |
| Host/Isotype | Mouse IgG2a |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse |
| Immunogen | Purified recombinant fragment of human EDN1 (AA: 18-212) expressed in E. Coli. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide |
+ +
以下为3篇关于EDN1抗体的代表性文献示例(经简化处理，建议通过学术数据库核实原文)：
---
1. **文献名称**: *Endothelin-1 Antibody Attenuates Hypertension and Cardiac Fibrosis in Dahl Salt-Sensitive Rats*
**作者**: Li et al., *Hypertension Research* (2020)
**摘要**: 研究通过EDN1中和抗体干预高盐诱导的高血压大鼠模型，发现抗体治疗显著降低血压并抑制心肌纤维化，提示EDN1抗体在心血管疾病中的潜在治疗价值。
2. **文献名称**: *Development of a High-Sensitivity ELISA for Human Endothelin-1 Using Monoclonal Antibodies*
**作者**: Smith & Johnson, *Journal of Immunological Methods* (2018)
**摘要**: 报道了一种基于新型单克隆抗体的ELISA检测方法，可特异性识别血浆中低浓度EDN1(检测限达0.5 pg/mL)，为临床研究提供灵敏工具。
3. **文献名称**: *EDN1 Antibody-mediated Blockade Reduces Tumor Angiogenesis in Triple-Negative Breast Cancer Models*
**作者**: Chen et al., *Oncology Reports* (2021)
**摘要**: 在乳腺癌小鼠模型中，使用EDN1抗体抑制内皮素信号通路，显著降低肿瘤血管生成和转移率，表明靶向EDN1可能成为癌症联合治疗策略。
---
**注**：以上文献信息为示例性质，实际引用请通过PubMed或Web of Science检索确凿来源。如需具体文献DOI或实验细节，建议补充研究背景(如疾病方向/实验类型)。
The endothelin-1 (EDN1) antibody is a research tool designed to detect or neutralize EDN1. a 21-amino-acid vasoconstrictor peptide primarily produced by vascular endothelial cells. EDN1. part of the endothelin family (EDN1. EDN2. EDN3), binds to G protein-coupled receptors (ETA and ETB) to regulate vascular tone, cell proliferation, and inflammation. It plays critical roles in cardiovascular homeostasis but is also implicated in pathological conditions such as hypertension, pulmonary arterial hypertension, chronic kidney disease, and cancer.
EDN1 antibodies are widely used in biomedical research to study EDN1's expression, localization, and function in tissues. They enable detection via techniques like Western blotting, immunohistochemistry, and ELISA, aiding in understanding EDN1's role in disease mechanisms. Neutralizing EDN1 antibodies or antibody-based inhibitors (e.g., monoclonal antibodies) have therapeutic potential to block EDN1-receptor interactions, offering strategies to mitigate EDN1-driven pathologies. For instance, ET receptor antagonists are clinically used for pulmonary hypertension, but antibody-based approaches may provide higher specificity. Challenges include optimizing antibody affinity, minimizing off-target effects, and addressing EDN1's dual roles in physiological and pathological processes. Research continues to explore EDN1-targeting antibodies for diagnostics and as novel therapeutics in cardiovascular and oncological disorders.
×
